The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC)
Project Number5U54EB034652-02
Contact PI/Project LeaderRICHARDS-KORTUM, REBECCA R. Other PIs
Awardee OrganizationRICE UNIVERSITY
Description
Abstract Text
Abstract:
Cancer is the first or second leading cause of premature death in 134 of 183 countries, and it is estimated that global
incidence of cancer will increase by 50% from 2018 to 2040. The number of cases is projected to double in countries with
low Human Development Index; these countries have the least resources and infrastructure to adequately care for cancer
patients. Disparities exist within countries; in the US, racial and ethnic minorities and other medically underserved
populations share a disproportionate burden for many types of cancer. Most cancers can be cured if detected early and
treated effectively. To reduce premature death, the World Health Organization recommends implementing early cancer
detection and prevention programs at the primary care level. Yet, existing tests for early cancer detection are too complex
and/or expensive to implement in primary care settings, particularly in medically underserved areas. We will establish the
Center for Innovation and Translation of Point-of-Care Technologies for Equitable Cancer Care (CITEC) to identify high-
priority clinical needs for POC cancer technologies; to accelerate development of effective, affordable technologies to
meet these needs; to evaluate and improve the clinical and public health impact of POC technologies in diverse settings;
and to train developers and users to create and disseminate more equitable POC technologies. CITEC will prioritize
development of POC tests to detect cancers that arise in epithelial surfaces. Initially, we will focus on sites accessible for
early detection because this is where POC technologies can have the most immediate impact. Targeted organ sites include
the uterine cervix, gastro-intestinal tract (esophagus, stomach, colon, rectum, anus), and oral cavity; cancers in these sites
account for 26% of global cases and 29% of global cancer deaths. CITEC builds on the highly productive 15-year
collaboration between Rice University, The University of Texas MD Anderson Cancer Center, Baylor College of Medicine,
and The University of Texas Health Science Center at Houston to develop and translate novel POC technologies to improve
cancer care in both low- and high-resource settings. Joining with collaborators in Brazil at The University of Sao Paulo and
Barretos Cancer Hospital and partners in Mozambique at The Universidade Eduardo Mondlane and Ministry of Health, we
will create a collaborative center to support technology development and engage and support a global community of
investigators dedicated to creating and scaling POC technologies for equitable cancer screening and diagnosis to facilitate
early treatment. CITEC will support development of POC technologies to promote high priority topics of NIH cancer
research, including precision approaches to prevention, screening and early detection, reducing disparities in cancer
outcomes, and building a diverse workforce able to translate POC technologies from research and development to
equitable implementation. CITEC will have a major impact on equitable prevention, diagnosis and early treatment of
cancer in the US and worldwide, and will work with the POCTRN network to build a strong team of global partners to
strengthen and sustain POC technology development.
Public Health Relevance Statement
Narrative:
Early detection of cancer and pre-cancerous lesions improves outcomes and reduces the cost and pain associated with
treatment. Better tools are needed to improve early detection of cancer at the point-of-care, especially in medically
underserved communities. The Center for Innovation and Translation of Point-of-Care Technologies for Equitable Cancer
Care (CITEC) will accelerate the development and adoption of new technologies that can be used to improve the early
detection of cancer in low-resource settings in the US and globally.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccelerationAccountingAddressAdoptionAnusAwardBrazilCancer DetectionCancer HospitalCancer PatientCaringCervix UteriCessation of lifeClinicalCollaborationsColonCommunitiesComplexCountryDedicationsDevelopmentDiagnosisDiseaseDisparityDiverse WorkforceEarly DiagnosisEarly treatmentEngineeringEnsureEpitheliumEquityEsophagusEvaluationGastrointestinal tract structureGoalsHealthHealth SciencesHuman DevelopmentIncidenceIndustrializationInfrastructureLesionMalignant NeoplasmsMedically Underserved AreaMedicineMozambiqueOral cavityOrganOutcomePainPalliative CarePerformancePoint of Care TechnologyPreventionPrevention approachPrevention programPrimary CareProcessProductivityPublic HealthRecommendationRectumResearchResearch PersonnelResource-limited settingResourcesRiceScientistScreening for cancerSiteStomachSuggestionSurfaceSustainable DevelopmentTechnologyTestingTexasTrainingTranslatingTranslationsUnited States National Institutes of HealthUniversitiesUniversity of Texas M D Anderson Cancer CenterWorkWorld Health Organizationanti-cancer researchcancer carecancer health disparitycancer preventioncancer therapycancer typecollegecommercializationcostdisparity reductionethnic minorityimplementation barriersimprovedimproved outcomeindexinginnovationlow and middle-income countriesmedically underservedmedically underserved populationmeetingsmembermortalitynew technologynovelpersonalized approachpoint of carepoint of care testingpremalignantprematurepreventable deathprevention serviceprimary care settingprototyperacial minorityscreeningtechnology developmenttechnology research and developmenttooltraining opportunityunderserved communityusability
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
050299031
UEI
K51LECU1G8N3
Project Start Date
13-September-2023
Project End Date
31-July-2028
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$1,300,000
Direct Costs
$915,389
Indirect Costs
$384,611
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$1,300,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54EB034652-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54EB034652-02
Patents
No Patents information available for 5U54EB034652-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54EB034652-02
Clinical Studies
No Clinical Studies information available for 5U54EB034652-02
News and More
Related News Releases
No news release information available for 5U54EB034652-02
History
No Historical information available for 5U54EB034652-02
Similar Projects
No Similar Projects information available for 5U54EB034652-02